Abbott CEO On GLP-1's Says 'Sees An Opportunity Here To Be Able To Develop Nutritional Product Or Other Products That Can Help Address Muscle Mass Loss'; On GLP-1 Drugs Vs Glucose Monitors: "I Think The Concerns Are Overblown."
Portfolio Pulse from Benzinga Newsdesk
During a conference call, the CEO of Abbott expressed interest in developing nutritional or other products to address muscle mass loss, leveraging GLP-1's. He also commented on the concerns about GLP-1 drugs versus glucose monitors, stating that he believes the concerns are overblown.
October 18, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott's CEO sees potential in GLP-1's for developing products to address muscle mass loss. He also downplayed concerns about GLP-1 drugs versus glucose monitors.
The CEO's comments indicate a potential new direction for product development at Abbott, which could lead to increased revenues if successful. His dismissal of concerns about GLP-1 drugs versus glucose monitors could also reassure investors and potentially boost the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100